Cost-effectiveness of low-level laser therapy (LLLT) in head and neck cancer patients receiving concurrent chemoradiation
Antunes HS, Schluckebier LF, Herchenhorn D, Small IA, Araújo CM, Viégas CM, Rampini MP, Ferreira EM, Dias FL, Teich V, Teich N, Ferreira CG
Oral oncology · 39 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2015-11-11 · Oral Oncol · vol. 52 · págs. 85–90
- Editorial
- Elsevier BV
- Citado
- 66 citas · más que el 85% de estudios similares · 1.7× el promedio de su campo
- Referencias
- 26 trabajos
- Acceso
- De pago
- Áreas de investigación
- Oral health in cancer treatment · Head and Neck Cancer Studies · Health Systems, Economic Evaluations, Quality of Life
- Palabras clave
- low-level laser therapy, head and neck squamous cell carcinoma, oral mucositis, concurrent chemoradiotherapy, cisplatin, cost-effectiveness, laser diode, opioid use, gastrostomy tube feeding, hospital costs, Unified Health System (SUS)
- MeSH
- humans, carcinoma, squamous cell, head and neck neoplasms, treatment outcome, prospective studies, double-blind method, aged, middle aged, cost-benefit analysis, brazil, female, male, mucositis, chemoradiotherapy, low-level light therapy
12 autores
- Héliton Spíndola Antunes🇧🇷 · autor de correspondenciaInstituto Nacional de Câncer - INCA
- Luciene Fontes Schluckebier🇧🇷Instituto Nacional de Câncer - INCA
- Daniel Herchenhorn🇧🇷Instituto Nacional de Câncer - INCA
- Isabele Avila Small🇧🇷Instituto Nacional de Câncer - INCA
- Carlos M. Araújo🇧🇷Instituto Nacional de Câncer - INCA
- Celia Maria Pais Viegas🇧🇷Instituto Nacional de Câncer - INCA
- Mariana Pereira Rampini🇧🇷Instituto Nacional de Câncer - INCA
- Elza Maria de Sá Ferreira
- Fernando Luiz Dias🇧🇷Instituto Nacional de Câncer - INCA
- Vanessa Teich
- Nelson Teich
- Carlos Gil Ferreira🇧🇷D’Or Institute for Research and Education; Instituto Nacional de Câncer - INCA
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Oral mucositis is a major event increasing treatment costs of head and neck squamous cell carcinoma (HNSCC) patients treated with chemoradiation (CRT). This study was designed to estimate the cost-effectiveness of low-level laser therapy (LLLT) to prevent oral mucositis in HNSCC patients receiving CRT.
Methods
From June 2007 to December 2010, 94 patients with HNSCC of nasopharynx, oropharynx, and hypopharynx entered a prospective, randomized, double blind, placebo-controlled, phase III trial. CRT consisted of conventional radiotherapy (RT: 70.2 Gy, 1.8 Gy/d, 5 times/wk)+concurrent cisplatin (100mg/m2) every 3 weeks. An InGaAlP (660 nm-100 mW-4J/cm2) laser diode was used for LLLT.
Results
From the perspective of Brazil's public health care system (SUS), total costs were higher in Placebo Group (PG) than Laser Group (LG) for opioid use (LG=US$ 9.08, PG=US$ 44.28), gastrostomy feeding (LG=US$ 50.50, PG=US$ 129.86), and hospitalization (PG=US$ 77.03). In LG, the cost was higher for laser therapy only (US$ 1880.57). The total incremental cost associated with the use of LLLT was US$ 1689.00 per patient. The incremental cost-effectiveness ratio (ICER) was US$ 4961.37 per grade 3-4 OM case prevented compared to no treatment.
Conclusions
Our results indicate that morbidity was lower in the Laser Group and that LLLT was more cost-effective than placebo up to a threshold of at least US$ 5000 per mucositis case prevented.
Clinical trial information
NCT01439724.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.